We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Out of joint

11 February 2019 By Dasha Afanasieva

The medical services group’s shares fell on a report that it may buy U.S. surgery specialist NuVasive. A takeover would take the company into a market it doesn’t know, and need years to pay off. New CEO Namal Nawana would do better to focus on smaller, less risky M&A.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)